BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Tangible Net Worth Ratio
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Tangible Net Worth Ratio of 91.2% as of December 2024. This metric is calculated by deducting intangible assets (€4.72 Billion) from net assets (€53.63 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore BEXIMCO PHARMA.GDR REGS 1 (R2WA) equity growth momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
BEXIMCO PHARMA.GDR REGS 1 Tangible Net Worth Ratio (2021–2024)
This chart shows how BEXIMCO PHARMA.GDR REGS 1's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 91.2%, reflecting net assets of €53.63 Billion with intangible assets of €4.72 Billion EUR. For live market cap and overall valuation, see BEXIMCO PHARMA.GDR REGS 1 (R2WA) total market value.
Annual Tangible Net Worth Ratio for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore BEXIMCO PHARMA.GDR REGS 1 capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.9% | €51.90 Billion | €4.72 Billion | €69.34 Billion | ▲ +0.8 pp |
| 2023 | 90.1% | €47.62 Billion | €4.72 Billion | €69.16 Billion | ▲ +0.7 pp |
| 2022 | 89.4% | €44.64 Billion | €4.73 Billion | €66.15 Billion | ▼ -6.9 pp |
| 2021 | 96.3% | €37.36 Billion | €1.38 Billion | €52.25 Billion | — |